Wikipedia -WSS

Wikipedia

author：explore 2025-09-27 12:56:00 - browse：86391

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Massive project maps cells in human brain in unprecedented detail

hotspot

WSS

What's changing in Medicare's open enrollment this year?

What the Wegovy shortage looks like for doctors — and for patients

How doctors and nurses shape Google's AI

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Akero's treatment for NASH falls short in cirrhosis study

A revolution in caring for preterm infants

hotspot

Wikipedia

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Massive project maps cells in human brain in unprecedented detail

Sports medicine is finally prioritizing gender equality

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Activists slam private health insurers over coverage restrictions

A revolution in caring for preterm infants

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

There’s no way to know how good AI health technologies are

explore

What the Wegovy shortage looks like for doctors — and for patients

The thinking behind the controversial eating disorder chatbot Tessa

Medicare to cover more brain scans related to Alzheimer’s drugs

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Female surgeons have lower rates of long

Senate panel passes drug pricing bills, but drops one PBM reform

entertainment

hotspot

focus

entertainment